Literature DB >> 18097165

Mutations in LRRK2 as a cause of Parkinson's disease.

Benoit I Giasson1, Vivianna M Van Deerlin.   

Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common known cause of late-onset Parkinson's disease (PD). Clinical and pathological studies have demonstrated that in the majority of cases LRRK2 mutations lead to PD with classical clinical and pathological features. However, in some patients the pathological features can be distinct and/or more extensive than typically seen in PD. Collectively, these findings provide important clues into the mechanisms by which LRRK2 mutations can lead to demise of dopaminergic neurons. The understanding of LRRK2 protein function and its gene regulation and the consequences of mutations are still at their infancy, but scientific findings are progressing at a rapid pace. Although more detailed information on LRRK2 is still needed in the quest for therapeutic intervention that could halt or slow the progression of disease, here we summarize the current information on the biological and pathological properties of LRRK2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18097165     DOI: 10.1159/000109764

Source DB:  PubMed          Journal:  Neurosignals        ISSN: 1424-862X


  22 in total

Review 1.  Neuroproteomics as a promising tool in Parkinson's disease research.

Authors:  Ilse S Pienaar; William M U Daniels; Jürgen Götz
Journal:  J Neural Transm (Vienna)       Date:  2008-06-04       Impact factor: 3.575

2.  The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.

Authors:  Jason P Covy; Benoit I Giasson
Journal:  J Neurochem       Date:  2010-08-19       Impact factor: 5.372

Review 3.  α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.

Authors:  Jason P Covy; Benoit I Giasson
Journal:  Neurotoxicology       Date:  2011-01-14       Impact factor: 4.294

4.  LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients.

Authors:  Soraya Bardien; Angelica Marsberg; Rowena Keyser; Debbie Lombard; Suzanne Lesage; Alexis Brice; Jonathan Carr
Journal:  J Neural Transm (Vienna)       Date:  2010-06-11       Impact factor: 3.575

5.  Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics.

Authors:  Chun-Xiang Wu; Jingling Liao; Yangshin Park; Xylena Reed; Victoria A Engel; Neo C Hoang; Yuichiro Takagi; Steven M Johnson; Mu Wang; Mark Federici; R Jeremy Nichols; Ruslan Sanishvili; Mark R Cookson; Quyen Q Hoang
Journal:  J Biol Chem       Date:  2019-02-22       Impact factor: 5.157

6.  Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions.

Authors:  Elisa A Waxman; Jason P Covy; Irene Bukh; Xiaojie Li; Ted M Dawson; Benoit I Giasson
Journal:  J Neuropathol Exp Neurol       Date:  2009-07       Impact factor: 3.685

7.  Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis.

Authors:  Loukia Parisiadou; Chengsong Xie; Hyun Jin Cho; Xian Lin; Xing-Long Gu; Cai-Xia Long; Evy Lobbestael; Veerle Baekelandt; Jean-Marc Taymans; Lixin Sun; Huaibin Cai
Journal:  J Neurosci       Date:  2009-11-04       Impact factor: 6.167

8.  MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.

Authors:  Hyun Jin Cho; Guoxiang Liu; Seok Min Jin; Loukia Parisiadou; Chengsong Xie; Jia Yu; Lixin Sun; Bo Ma; Jinhui Ding; Renée Vancraenenbroeck; Evy Lobbestael; Veerle Baekelandt; Jean-Marc Taymans; Ping He; Juan C Troncoso; Yong Shen; Huaibin Cai
Journal:  Hum Mol Genet       Date:  2012-11-02       Impact factor: 6.150

9.  Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain.

Authors:  Jingling Liao; Chun-Xiang Wu; Christopher Burlak; Sheng Zhang; Heather Sahm; Mu Wang; Zhong-Yin Zhang; Kurt W Vogel; Mark Federici; Steve M Riddle; R Jeremy Nichols; Dali Liu; Mark R Cookson; Todd A Stone; Quyen Q Hoang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-03       Impact factor: 11.205

Review 10.  Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.

Authors:  Thomas Kramer; Fabio Lo Monte; Stefan Göring; Ghislaine Marlyse Okala Amombo; Boris Schmidt
Journal:  ACS Chem Neurosci       Date:  2012-01-18       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.